NCT00431067 - Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2009

Conditions

Breast Neoplasms

Interventions

DRUG

BIBW 2992

Trial Locations (12)

1200.11.3 Boehringer Ingelheim Investigational Site, Scottsdale

1200.11.7 Boehringer Ingelheim Investigational Site, Encinitas

1200.11.4 Boehringer Ingelheim Investigational Site, Santa Monica

1200.11.2 Boehringer Ingelheim Investigational Site, Tampa

1200.11.1 Boehringer Ingelheim Investigational Site, Boston

1200.11.5 Boehringer Ingelheim Investigational Site, Chapel Hill

1200.11.4401 Boehringer Ingelheim Investigational Site, Bournemouth

1200.11.4402 Boehringer Ingelheim Investigational Site, Crownhill, Plymouth

1200.11.4406 Boehringer Ingelheim Investigational Site, Guildford

1200.11.4405 Boehringer Ingelheim Investigational Site, London

1200.11.4404 Boehringer Ingelheim Investigational Site, Poole

1200.11.4403 Boehringer Ingelheim Investigational Site, Truro